About Aurigene Oncology Limited
Data last updated: 22 December 2025
Aurigene Oncology Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Dr.Reddy's Laboratories Ltd. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 10 August 2001, the company has been in operation for over 25 years.
Registered with ROC Bangalore under CIN U24239KA2001PLC029391.
Capital: an authorised share capital of ₹240 Cr and a paid-up capital of ₹187.56 Cr. Formerly known as Aurigene Discovery Technologies P Limited. It is led by directors including Bruce Leonard Andrews Carter and Venkata Ramana Motupalli.
Last AGM: 26 July 2024. Financial statements filed for year ended 31 March 2024. Office: 39/49(P)Kiadb Industrial Area Electronics City Phase Ii, Bangalore, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹171.93 Cr, a decline of 57% compared to the previous year.
The company has a workforce of approximately 479 employees as per the latest available data. It operates as a subsidiary of Dr.Reddy's Laboratories Ltd. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Aurigene. As per MCA filings, the company has satisfied charges of ₹6.59 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurigene.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered Address39/49(P)Kiadb Industrial Area Electronics City Phase Ii, Bangalore, Karnataka, India – 560100
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Aurigene Oncology Limited
Aurigene Oncology Limited has one previous CIN (Corporate Identification Number): U24239KA2001PTC029391. The current CIN is U24239KA2001PLC029391, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239KA2001PLC029391 | Current |
| U24239KA2001PTC029391 | Previous |
Associated Brands with Aurigene Oncology Limited
Aurigene Oncology Limited operates one associated brand: Aurigene. These brands represent Aurigene Oncology Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Discovers and develops novel oncology therapeutics via research collaborations. | aurigene.com |
Competitors & Alternatives of Aurigene Oncology Limited
Brands and companies operating in the same space as Aurigene Oncology Limited include Sutro Biopharma, Synthego, Avidity Biosciences and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Sutro Biopharma
|
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | United States | 2003 |
Synthego
|
CRISPR-engineered cell and gene therapies are developed for research applications. | Redwood City, United States, United States | 2012 |
Avidity Biosciences
|
Antibody-siRNA complexes are developed for cancer treatment. | San Diego, United States, United States | 2012 |
Antheia
|
Yeast cells are genetically engineered to produce medicinal products. | Palo Alto, United States, United States | 2013 |
Vividion Therapeutics
|
Developing novel drugs based on a proteome-wide ligand and target discovery platform | Oceanside, United States, United States | 2016 |
Korro Bio
|
RNA-editing technologies are provided for precision medicine applications. | Cambridge, United States, United States | 2018 |
Straumann Group
|
Dental implants and regenerative dentistry products are developed. | Basel, Switzerland, Switzerland | 1954 |
Judges Scientific
|
Acquisition and development of scientific instrument businesses is conducted. | London, United Kingdom, United Kingdom | 2002 |
Savara Pharma
|
Therapeutics for rare respiratory diseases are developed by Savara Pharma. | Austin, United States, United States | 2008 |
Univercells
|
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | Charleroi, Belgium, Belgium | 2013 |
Business Activity of Aurigene Oncology Limited
Aurigene Oncology Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details for Aurigene Oncology Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Aurigene Oncology Limited
Aurigene Oncology Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S.R. Batliboi & Associates LLP | Locked | Locked | Locked |
Complete auditor history for Aurigene Oncology Limited
Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors and KMP of Aurigene Oncology Limited
Aurigene Oncology Limited currently reports 7 directors and 1 key managerial person. 25 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bruce Leonard Andrews Carter | Director | 30 Mar 2015 | 11 Years 4 Months | Current |
| Venkata Ramana Motupalli | Director | 19 Oct 2023 | 2 Years 9 Months | Current |
|
Satish Reddy Kallam
Also directs:
Dr.Reddy's Laboratories Ltd, Greenpark Hotels And Resorts Limited, Stamlo Industries Limited and 5 more
|
Director | 10 Aug 2001 | 25 Years 0 Months | Current |
| Kumar Srinivasan | Director | 01 Oct 2022 | 3 Years 10 Months | Current |
| Shubhada Vivek Chiplunkar | Director | 01 Oct 2022 | 3 Years 10 Months | Current |
|
Muralidhara Ramachandra
Also directs:
Dr.Reddy's Institute Of Life Sciences
|
Ceo | 01 Jul 2019 | 7 Years 1 Months | Current |
Financials of Aurigene Oncology Limited FY 2024 filings available
Aurigene Oncology Limited reported revenue of ₹171.93 Cr (down 57.00% YoY) for FY 2025.
Ten-year financial statements for Aurigene Oncology Limited
Historical statement values and trend charts require an active report plan.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Aurigene Oncology Limited
Shareholding and ownership data for Aurigene Oncology Limited
Promoter, institutional, public, and beneficial ownership values require an active report plan.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Group Structure of Aurigene Oncology Limited
Aurigene Oncology Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Aurigene Oncology Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Aurigene Pharmaceutical Services Limited | U74999KA2019PLC127964 | Locked |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Aurigene Oncology Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Sep 2011 | State Bank of India | ₹6.5 Cr | Satisfied |
| 21 Oct 2005 | Icici Bank Limited | ₹8.75 Lakh | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Aurigene Oncology Limited
Aurigene Oncology Limited has a workforce of 479 employees as of Apr 06, 2024.
Employee and EPFO history for Aurigene Oncology Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Aurigene Oncology Limited
GST registrations and filing compliance for Aurigene Oncology Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Aurigene Oncology Limited
Credit ratings, litigation, and regulatory alerts for Aurigene Oncology Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Aurigene Oncology Limited
MSME payment history for Aurigene Oncology Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Aurigene Oncology Limited
Corporate group structure for Aurigene Oncology Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Aurigene Oncology Limited
MCA filings and documents for Aurigene Oncology Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Aurigene Oncology Limited
Recent News on Aurigene Oncology Limited
Frequently Asked Questions about Aurigene Oncology Limited
Aurigene Oncology Limited is an active public limited company in the life sciences sector based in Bangalore, Karnataka, India. It was incorporated on 10 August 2001 (25+ years old) and is registered under CIN U24239KA2001PLC029391. The company has 479 employees.
Aurigene Oncology Limited reported revenue of ₹171.93 Cr for FY 2025 (down 57.00% YoY).
The current directors and KMP of Aurigene Oncology Limited are:
- Bruce Leonard Andrews Carter - Director
- Venkata Ramana Motupalli - Director
- Satish Reddy Kallam - Director
- Kumar Srinivasan - Director
- Shubhada Vivek Chiplunkar - Director
- Muralidhara Ramachandra - Ceo
- Venkateswara Prasad Gunupati - Director
- Buggana Hariharnath - Director
The primary industry of Aurigene Oncology Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Aurigene Oncology Limited can be reached at the registered office: 3949PKiadb Industrial Area Electronics City Phase Ii, Bangalore, Karnataka, India – 560100, or through the website aurigene.com.
The authorised capital is ₹240 Cr, and the paid-up capital is ₹187.56 Cr.